Equities

Eiger BioPharmaceuticals Inc

Eiger BioPharmaceuticals Inc

Actions
  • Price (USD)8.98
  • Today's Change0.00 / 0.00%
  • Shares traded287.79k
  • 1 Year change-16.31%
  • Beta1.6104
Data delayed at least 15 minutes, as of Oct 29 2020 20:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Eiger BioPharmaceuticals Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing drugs for serious diseases. Its product candidate pipeline includes programs, including Lonafarnib (LNF), Peginterferon Lambda (lambda), LNF in Progeria and Progeroid Laminopathies (PL), Avexitide. LNF is an orally bioavailable, farnesylation inhibitor in Phase-III clinical trials for Hepatitis Delta Virus (HDV) infection. Lambda is a late-stage, type III interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections. It is also developing lonafarnib for treatment of Progeria and Progeroid Laminopathies. Avexitide is a peptide that it is being developed as a treatment for Post-Bariatric Hypoglycemia (PBH). Avexitide is also being developed for Congenital Hyperinsulinism (CHI).

  • Revenue in USD (TTM)0.00
  • Net income in USD-66.10m
  • Incorporated2012
  • Employees28.00
  • Location
    Eiger BioPharmaceuticals Inc2155 Park BlvdPALO ALTO 94306-1543United StatesUSA
  • Phone+1 (650) 279-9845
  • Fax+1 (650) 618-1621
  • Websitehttp://www.eigerbio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Agile Therapeutics Inc0.00-29.16m250.54m15.00--3.17-----0.4054-0.40540.000.92550.00----0.00-45.57-52.52-48.72-63.58-----------31.330.1634------5.93--0.4677--
Calithera Biosciences Inc0.00-86.86m254.01m93.00--1.80-----1.44-1.440.002.030.00----0.00-52.43-40.33-58.68-45.98-------503.98----0.00---100.00---64.49---58.31--
Checkmate Pharmaceuticals Inc-100.00bn-100.00bn255.33m22.00--------------3.55----------------------------0.00-------39.48------
XOMA Corp10.53m-9.43m258.71m11.00--6.85--25.00-0.9633-0.96331.083.480.1267--7.041,052,500.00-11.35-24.56-13.17-35.09-----89.63-54.50---4.500.4475--246.67-0.531485.15------
Kezar Life Sciences Inc0.00-38.24m260.42m40.00--1.66-----1.51-1.510.003.450.00----0.00-27.95---28.99--------------0.00-------51.45------
Eiger Biopharmaceuticals Inc0.00-66.10m269.91m28.00--4.29-----2.68-2.680.002.150.00----0.00-56.00-73.03-63.98-84.77-----------33.180.3448-------34.09--175.37--
Lannett Company, Inc.545.74m-33.37m272.70m954.00--0.854411.660.4916-0.871-0.87113.967.810.46972.653.76572,058.70-2.87-3.22-3.45-3.7730.2742.50-6.11-7.251.400.85550.6922---16.736.0587.74--8.07--
Kalvista Pharmaceuticals Inc9.32m-32.59m273.99m56.00--3.79--30.30-1.83-1.830.52254.160.0915--0.7379166,446.40-31.99---35.94-------349.66------0.00---21.31---39.87------
NuCana PLC (ADR)0.00-28.19m277.01m31.00--2.36-----0.8703-0.87030.002.260.00----0.00-30.00---33.01--------------0.0117-------54.71------
Gamida Cell Ltd0.00-50.46m280.51m79.00--3.86-----1.26-1.260.001.510.00----0.00-60.53---70.26--------------0.00------35.10------
Aldeyra Therapeutics Inc0.00-49.26m280.86m20.00--4.36-----1.75-1.750.001.600.00----0.00-67.73-65.10-73.44-72.29-----------79.990.2191-------56.39---7.48--
BioNexus Gene Lab Coporation83.76k-229.10k282.51m5.00--270.15--3,127.55-0.0025-0.00250.00090.00940.06514.854.4516,752.00-17.81---18.61--21.75---273.52--15.97--0.0562---40.21---1,031.83------
Imara Inc0.00-39.15m282.91m16.00--2.60-----5.75-5.750.006.140.00----0.00-39.81---42.10--------------0.00-------106.96------
Cabaletta Bio Inc0.00-25.69m287.27m31.00--2.28-----1.08-1.080.005.190.00----0.00-24.97---25.61--------------0.00-------82.50------
Data as of Oct 29 2020. Currency figures normalised to Eiger BioPharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

33.77%Per cent of shares held by top holders
HolderShares% Held
683 Capital Management LLCas of 30 Jun 20202.16m7.38%
BlackRock Fund Advisorsas of 30 Jun 20201.75m5.98%
The Vanguard Group, Inc.as of 30 Jun 20201.24m4.23%
Mangrove Partnersas of 30 Jun 2020947.85k3.24%
Citadel Advisors LLCas of 30 Jun 2020883.30k3.02%
Cormorant Asset Management LPas of 30 Jun 2020700.00k2.39%
Soleus Capital Management LP (Investment Management)as of 30 Jun 2020620.27k2.12%
Assenagon Asset Management SA (Germany)as of 30 Sep 2020555.18k1.90%
Knoll Capital Management LPas of 30 Jun 2020525.24k1.80%
Adage Capital Management LPas of 30 Jun 2020500.00k1.71%
More ▼
Data from 30 Jun 2020 - 30 Sep 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.